Logo image of SGMA

SIGMATRON INTERNATIONAL INC (SGMA) Stock Fundamental Analysis

NASDAQ:SGMA - Nasdaq - US82661L1017 - Common Stock - Currency: USD

3.01  +0 (+0.17%)

Fundamental Rating

2

Taking everything into account, SGMA scores 2 out of 10 in our fundamental rating. SGMA was compared to 125 industry peers in the Electronic Equipment, Instruments & Components industry. SGMA may be in some trouble as it scores bad on both profitability and health. SGMA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SGMA has reported negative net income.
SGMA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: SGMA reported negative net income in multiple years.
In multiple years SGMA reported negative operating cash flow during the last 5 years.
SGMA Yearly Net Income VS EBIT VS OCF VS FCFSGMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -6.35%, SGMA is doing worse than 60.00% of the companies in the same industry.
With a Return On Equity value of -21.28%, SGMA is not doing good in the industry: 65.60% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -6.35%
ROE -21.28%
ROIC N/A
ROA(3y)-1.8%
ROA(5y)-0.88%
ROE(3y)-7.6%
ROE(5y)-3.93%
ROIC(3y)N/A
ROIC(5y)N/A
SGMA Yearly ROA, ROE, ROICSGMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

SGMA's Operating Margin has improved in the last couple of years.
SGMA's Gross Margin of 7.42% is on the low side compared to the rest of the industry. SGMA is outperformed by 84.00% of its industry peers.
In the last couple of years the Gross Margin of SGMA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SGMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.42%
OM growth 3Y15.94%
OM growth 5Y12.33%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.13%
GM growth 5Y-0.18%
SGMA Yearly Profit, Operating, Gross MarginsSGMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10

More info and screens

3

2. Health

2.1 Basic Checks

SGMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
SGMA has more shares outstanding than it did 1 year ago.
SGMA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SGMA has an improved debt to assets ratio.
SGMA Yearly Shares OutstandingSGMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
SGMA Yearly Total Debt VS Total AssetsSGMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 1.93 indicates that SGMA is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.93, SGMA is not doing good in the industry: 72.00% of the companies in the same industry are doing better.
SGMA has a debt to FCF ratio of 2.38. This is a good value and a sign of high solvency as SGMA would need 2.38 years to pay back of all of its debts.
The Debt to FCF ratio of SGMA (2.38) is better than 74.40% of its industry peers.
SGMA has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.07, SGMA perfoms like the industry average, outperforming 56.80% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 2.38
Altman-Z 1.93
ROIC/WACCN/A
WACC10.85%
SGMA Yearly LT Debt VS Equity VS FCFSGMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

SGMA has a Current Ratio of 1.23. This is a normal value and indicates that SGMA is financially healthy and should not expect problems in meeting its short term obligations.
SGMA has a worse Current ratio (1.23) than 87.20% of its industry peers.
SGMA has a Quick Ratio of 1.23. This is a bad value and indicates that SGMA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.35, SGMA is not doing good in the industry: 96.80% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 0.35
SGMA Yearly Current Assets VS Current LiabilitesSGMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SGMA have decreased strongly by -1202.52% in the last year.
Looking at the last year, SGMA shows a very negative growth in Revenue. The Revenue has decreased by -22.02% in the last year.
Measured over the past years, SGMA shows a small growth in Revenue. The Revenue has been growing by 5.17% on average per year.
EPS 1Y (TTM)-1202.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%539.22%
Revenue 1Y (TTM)-22.02%
Revenue growth 3Y10.42%
Revenue growth 5Y5.17%
Sales Q2Q%-25.91%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SGMA Yearly Revenue VS EstimatesSGMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGMA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMA Price Earnings VS Forward Price EarningsSGMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SGMA is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, SGMA is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 0.78
EV/EBITDA 20.29
SGMA Per share dataSGMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40 50

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SIGMATRON INTERNATIONAL INC

NASDAQ:SGMA (7/21/2025, 8:00:02 PM)

3.01

+0 (+0.17%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)03-06 2025-03-06
Earnings (Next)07-23 2025-07-23
Inst Owners37.75%
Inst Owner Change-3.56%
Ins Owners18.85%
Ins Owner Change0%
Market Cap18.42M
Analysts0
Price TargetN/A
Short Float %1.97%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.06
P/FCF 0.78
P/OCF 0.75
P/B 0.32
P/tB 0.32
EV/EBITDA 20.29
EPS(TTM)-2.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)3.85
FCFY127.99%
OCF(TTM)4.03
OCFY133.74%
SpS50.93
BVpS9.4
TBVpS9.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.35%
ROE -21.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 7.42%
FCFM 7.56%
ROA(3y)-1.8%
ROA(5y)-0.88%
ROE(3y)-7.6%
ROE(5y)-3.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)14.02%
ROCE(5y)9.57%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y15.94%
OM growth 5Y12.33%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.13%
GM growth 5Y-0.18%
F-Score3
Asset Turnover1.62
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 2.38
Debt/EBITDA 1.14
Cap/Depr 17.46%
Cap/Sales 0.34%
Interest Coverage N/A
Cash Conversion 690.28%
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 0.35
Altman-Z 1.93
F-Score3
WACC10.85%
ROIC/WACCN/A
Cap/Depr(3y)59.02%
Cap/Depr(5y)70.3%
Cap/Sales(3y)0.93%
Cap/Sales(5y)1.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1202.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%539.22%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-22.02%
Revenue growth 3Y10.42%
Revenue growth 5Y5.17%
Sales Q2Q%-25.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-109.88%
EBIT growth 3Y28.02%
EBIT growth 5Y18.14%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y150.38%
FCF growth 3Y97.89%
FCF growth 5YN/A
OCF growth 1Y153.86%
OCF growth 3Y50.77%
OCF growth 5YN/A